Do these 3 things before closing this tab:
1Clear out junk files and repair common Windows errors2Fix the driver behind crashes, sound loss and screen glitches3Repair Windows errors before they cause bigger problemsTheranos was a blood-testing company founded by Elizabeth Holmes in 2003. Its central promise was that proprietary devices could run a broad range of clinical tests from a few drops of blood collected by finger stick, with results that were faster and more accurate or reliable than conventional laboratory testing. Federal trial evidence later showed a much narrower and less reliable system than those public claims suggested, including substantial use of conventional third-party laboratory machines.
The company’s story moved through separate civil and criminal proceedings. The Securities and Exchange Commission brought civil fraud charges in 2018; federal prosecutors then pursued criminal cases against Holmes and Sunny Balwani. Holmes was convicted on investor-related counts and sentenced to 135 months in prison. Balwani was convicted on counts involving investors and patients and sentenced to 155 months. Their verdicts, sentences and later appellate developments are related, but they are not identical legal records.
![Bad Blood: Secrets and Lies in a Silicon Valley Startup[John Carreyrou] - [Hardcover]](https://m.media-amazon.com/images/I/41bXYxuMj1L._SL160_.jpg)
What did Theranos claim its blood tests could do?
Theranos marketed a vision of decentralized, convenient laboratory testing. Holmes and Balwani described proprietary analyzers using names such as the Theranos Sample Processing Unit (TSPU), Edison and miniLab. The pitch was that a small finger-stick sample, rather than a conventional venous blood draw, could support a full range of clinical tests. They also presented the system as faster and more accurate or reliable than standard approaches.
Those statements describe what company leaders claimed, not an independent validation of performance. The distinction matters because the later federal record focused on whether the technology actually delivered the breadth, speed and reliability represented to investors, patients and business partners.
#1 Best Overall
The practical promise
- Small sample: blood collected by finger stick rather than a larger conventional draw.
- Broad menu: the suggestion that one proprietary platform could perform a wide range of clinical tests.
- Speed: results represented as arriving faster than those from conventional laboratory workflows.
- Reliability: claims that results would be more accurate or dependable than competing methods.
These four elements made the idea easy to understand and commercially powerful. They also created several separate questions for regulators and a jury: what the devices could run, how accurately they ran it, how quickly results were produced, and whether the company was using its own analyzers or other equipment behind the scenes.
How the technology story diverged from the courtroom record
The U.S. Department of Justice’s account of evidence at Holmes’s trial said the analyzers had accuracy and reliability problems, could perform only a limited number of tests, and were slower than some competing devices. The same account said Theranos resorted to conventional third-party machines for much of its testing. The Balwani trial release described similar evidence.
That is a summary of trial evidence and jury proceedings, not a standalone technical study of every Theranos instrument or test. It does, however, explain the central gap between the public pitch and the government’s criminal case: the issue was not merely whether a prototype worked in some circumstances, but whether the company represented a broad, dependable, proprietary service while relying on a more limited system and outside machines for substantial testing.
Why the distinction between claims and findings matters
Statements about the Edison, miniLab or TSPU should be labeled as company claims unless tied to a specific court finding or trial exhibit. Statements about performance limitations should be attributed to the federal trial record. Keeping those categories separate avoids turning an allegation, an evidentiary description and a verdict into the same thing.
PC Slower Than It Used to Be?
A free scan shows the junk files, broken settings and background clutter dragging Windows down - then fixes them in one click.Free scan · Windows 10 & 11Crashes, No Sound, or Screen Glitches?
Random freezes, missing sound and display glitches usually trace back to one bad driver. Find and replace yours safely.Free scan · under a minuteTheranos timeline: from founding to the criminal cases
| Date or period | What happened | How to read the record |
|---|---|---|
| 2003 | Elizabeth Holmes founded Theranos, a blood-testing business based in Palo Alto and Newark, California. | Established company history. |
| Technology-pitch period | Holmes and Balwani promoted the TSPU, Edison and miniLab as proprietary systems intended to run broad ranges of tests from finger-stick samples, with faster and more accurate or reliable results. | Descriptions of company claims; not independent validation. |
| Federal trial evidence | Evidence summarized by the Justice Department showed accuracy and reliability problems, a limited test menu, slower performance than some competing devices and use of conventional third-party machines for much testing. | Evidence presented in criminal proceedings, not a new laboratory study. |
| March 14, 2018 | The SEC charged Theranos, Holmes and Balwani, alleging that more than $700 million had been raised from investors through false or exaggerated statements about technology, business operations and financial performance. | Civil enforcement allegations. Theranos and Holmes agreed to resolve the charges without admitting or denying them; the SEC said it would litigate its claims against Balwani. |
| June 14, 2018 | Federal prosecutors announced criminal charges alleging separate schemes involving investors and patients. The indictment announcement alleged misrepresentations about testing, including claims that tests were performed on Theranos-manufactured analyzers, and about the company’s revenue prospects. | Criminal allegations at the indictment stage. |
| January 2022 | A jury found Holmes guilty of one conspiracy count and three wire-fraud counts in the investor-fraud case. | Criminal verdict. She was not convicted on every count with which she had been charged. |
| July 2022 | A jury found Balwani guilty of two conspiracy counts and 10 wire-fraud counts in schemes involving investors and patients. | Criminal verdict with a different scope from Holmes’s. |
| November 18, 2022 | Holmes was sentenced to 135 months, or 11 years and 3 months, in federal prison for defrauding investors. | Sentence imposed by the federal court. |
| December 2022 | Balwani was sentenced to 155 months, or 12 years and 11 months, in federal prison. | Sentence imposed by the federal court. |
| Later appellate reporting | The Associated Press reported that a federal appeals court rejected Holmes’s attempt to overturn her conviction and upheld Balwani’s conviction and a $452 million restitution order. | A later report, not a substitute for the current appellate docket. Custody and restitution status can change. |
What did the SEC allege in 2018?
On March 14, 2018, the SEC announced civil charges against Theranos, Holmes and Balwani. The agency alleged that the defendants raised more than $700 million from investors through a years-long scheme involving false or exaggerated statements about the technology, the company’s business and its financial performance.
The procedural outcome was not the same for all three defendants. Theranos and Holmes agreed to resolve the SEC’s charges without admitting or denying the allegations. The SEC said it would litigate its claims against Balwani. Because this was a civil enforcement action, the release’s allegations should not be presented as a criminal conviction or as a jury finding.
What the SEC case does—and does not—establish
- It establishes that the SEC formally accused the company and its two senior executives of securities-law violations.
- It establishes the SEC’s stated figure of more than $700 million allegedly raised from investors.
- It does not, by itself, establish criminal guilt.
- The resolution with Theranos and Holmes was made without admitting or denying the SEC’s allegations.
- The SEC’s civil case and the later federal criminal case were separate proceedings with different burdens, charges and outcomes.
What were the federal criminal charges?
On June 14, 2018, federal prosecutors announced an indictment alleging separate schemes involving investors and patients. According to the indictment announcement, the alleged misrepresentations included statements about what Theranos blood tests could do, whether testing was performed on Theranos-manufactured analyzers, and the company’s expected revenue and financial prospects.
An indictment is an allegation, not a finding. The criminal cases required prosecutors to prove the charged conspiracies and wire-fraud counts beyond a reasonable doubt. The later verdicts show which parts of those cases juries accepted, and they differed between Holmes and Balwani.
Recommended Free Tools
Holmes’s verdict and sentence
In January 2022, a jury found Holmes guilty of one count of conspiracy and three counts of wire fraud in the investor-fraud case. The verdict did not convict her on all charged counts, so descriptions such as “convicted of every Theranos fraud charge” are inaccurate.
The Justice Department’s trial account also described evidence about the analyzers’ limitations and the use of third-party machines. That evidence supplied the technology context for the investor case, but the legal verdict should still be stated precisely: one conspiracy count and three wire-fraud counts, all tied to the investor-fraud case.
On November 18, 2022, the federal court sentenced Holmes to 135 months—11 years and 3 months—in prison for defrauding investors. FBI Special Agent in Charge Craig Fair characterized the outcome by saying, “Elizabeth Holmes chose fraud over business failure.” That is an official characterization of the verdict, not an additional count or separate judicial finding.
Balwani’s verdict and sentence
In July 2022, a separate jury found Balwani guilty of two conspiracy counts and 10 wire-fraud counts. The schemes described in that verdict involved both investors and patients, giving the Balwani case a broader subject-matter scope than the investor-related counts on which Holmes was convicted.
Balwani’s trial release likewise summarized evidence that Theranos’s proprietary technology had important performance limitations and that conventional third-party machines were used for much testing. As with Holmes, those descriptions belong to the evidentiary record; the conviction counts themselves are the two conspiracy and 10 wire-fraud counts returned by the jury.
In December 2022, Balwani received a 155-month sentence—12 years and 11 months—in federal prison. The longer term does not mean the two juries returned identical verdicts or that the two defendants were convicted for exactly the same conduct.
Independent reader supportYour contribution helps us test, update, and keep practical guides available for everyone.Holmes and Balwani compared
| Issue | Elizabeth Holmes | Sunny Balwani |
|---|---|---|
| Conduct covered by the criminal verdict | Investor-fraud case. | Schemes involving investors and patients. |
| Convictions | One conspiracy count and three wire-fraud counts. | Two conspiracy counts and 10 wire-fraud counts. |
| Sentence | 135 months (11 years, 3 months), imposed November 18, 2022. | 155 months (12 years, 11 months), imposed December 2022. |
| Later appellate status | The Associated Press reported that a federal appeals court rejected her attempt to overturn the conviction. | The Associated Press reported that the court upheld his conviction and a $452 million restitution order. |
The table separates four questions that are often blurred in short summaries: whose conduct was at issue, what counts the jury actually returned, how long the sentence was, and what later appellate reporting said. The civil SEC allegations are not included in the conviction column because they came from a different proceeding.
Why did Theranos collapse?
Theranos collapsed as the gap widened between its public promise and the record developed through scrutiny and litigation. The company presented a proprietary platform capable of broad, fast, dependable finger-stick testing. Federal trial evidence described a limited test capability, accuracy and reliability problems, slower performance than some competing devices and substantial reliance on conventional machines.
That technology gap became inseparable from the company’s legal exposure. The SEC alleged that investors had been solicited with false or exaggerated statements about technology, business performance and finances. Federal prosecutors later alleged separate investor and patient schemes. Once those matters reached court, juries evaluated specific fraud and conspiracy counts rather than a general question of whether the startup’s vision was ambitious.
The result was a defunct company, civil enforcement history and two criminal cases with different verdicts. The verified record does not support adding unsourced estimates of the company’s peak valuation, total investor losses, number of affected patients or accuracy rates. Those figures are frequently repeated in popular accounts, but they are not established by the official figures summarized here.
How to describe the Theranos story accurately
- Say that finger-stick testing and broad test menus were company claims, not proven capabilities simply because executives announced them.
- Attribute limitations in accuracy, reliability, speed and test range to evidence presented at the federal trials.
- Identify the SEC action as a civil case and preserve the agency’s allegation that more than $700 million was raised through false or exaggerated statements.
- Identify the June 2018 indictment as an allegation stage, before either defendant’s jury verdict.
- Do not say Holmes was convicted on every charge; specify one conspiracy and three wire-fraud counts in the investor case.
- Do not merge the Holmes and Balwani verdicts; Balwani’s convictions covered investor and patient schemes.
- Carry the sentence units and dates with the figures: 135 months for Holmes and 155 months for Balwani.
- Treat appellate and custody information as time-sensitive. AP’s later report described the appellate outcomes, but the current docket and official custody information control any present-tense update.
Further reading
For a narrative account of the company’s rise and collapse, readers may consider Bad Blood: Secrets and Lies in a Silicon Valley Startup by John Carreyrou. It is optional background reading, not a replacement for the SEC releases, indictment materials, verdict records and sentencing documents that establish the legal chronology.
What the criminal case ultimately established
The criminal record established fraud convictions for both senior executives, but not an identical judgment against each. Holmes was found guilty on investor-related conspiracy and wire-fraud counts and received 135 months. Balwani was found guilty on conspiracy and wire-fraud counts involving investors and patients and received 155 months. The underlying technology issue remained central because the trial evidence described a system materially narrower and less reliable than the company’s broad finger-stick testing claims.
Quick wins for a faster PC:
Repair Windows errors before they cause bigger problemsFix Now →Scan for outdated or missing drivers - takes under a minuteDriver Scan →Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
Say something about this film